Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models

  • Epizyme Inc EPZM has reported positive data from mouse studies for potential first-in-class therapy, EPZ-719, that targets the enzyme SETD2.
  • The chromosomal abnormality is responsible for about 15% to 20% of multiple myeloma cases and is associated with poor patient prognosis.
  • Data were presented at the European Hematology Association virtual congress.
  • Epizyme tested EPZ-719 in mice bearing myeloma tumors with the mutation. The drug safely induced strong tumor growth inhibition of up to 95%.
  • Tumor regressions were observed in mice that got the drug at the top three doses tested.
  • The investigators also reported anti-tumor effects in two mouse models of myeloma without the mutation. The drug produced maximum tumor growth inhibition of 79% in one type and 92% in the other at a high dose.
  • Price Action: EPZM shares are up 2.99% at $8.79 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsmultiple myeloma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!